Research programme: Huntington's disease gene therapy - Neurologix

Drug Profile

Research programme: Huntington's disease gene therapy - Neurologix

Alternative Names: AAV-dXIAP

Latest Information Update: 10 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurologix
  • Class Gene therapies
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 16 Mar 2012 Discontinued - Preclinical for Huntington's disease in USA (Intracerebral)
  • 02 Jun 2011 Preclinical development is ongoing in USA
  • 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top